Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Core binding factor acute myeloid leukemia: the impact of age, leukocyte count, molecular findings, and minimal residual disease

6 May 2013

Abstract excerpt

PURPOSE: Most patients with acute myeloid leukemia (AML) and genetic rearrangements involving the core binding factor (CBF) have favorable prognosis. In contrast, a minority of them still have a high risk of leukemia recurrence. This study investigated the adverse features of CBF AML that could justify investigational therapeutic approaches. PATIENTS AND METHODS: One hundred and fifty patients (median age 42 yr,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Nuclear Structure and Function
Share to Retinoids in leukemia and cellular processes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 23646898
DOI: 10.1111/ejh.12130

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Core binding factor acute myeloid leukemia: the impact of age, leukocyte count, molecular findings, and minimal residual diseasePMID 23646898Read ↗

Core‐binding factor acute myeloid leukemia: Heterogeneity, monitoring, and therapySemantic proximity Read ↗

Core Binding Factor Acute Myeloid Leukemia: New Prognostic Categories and Therapeutic Opportunities.Semantic proximity Read ↗

Genetic abnormalities predict outcomes in patients with core binding factor acute myeloid leukemiaSemantic proximity Read ↗

Core Binding Factor AML Beyond Favorable Risk: Molecular Heterogeneity, MRD Dynamics, and Implications for Clinical Decision-MakingSemantic proximity Read ↗

Both the subtypes of KIT mutation and minimal residual disease are associated with prognosis in core binding factor acute myeloid leukemia: a retrospective clinical cohort study in single center.Semantic proximity Read ↗

Identification of molecular and cytogenetic risk factors for unfavorable core-binding factor-positive adult AML with post-remission treatment outcome analysis including transplantation.Semantic proximity Read ↗

Complex karyotype, older age, and reduced first‐line dose intensity determine poor survival in core binding factor acute myeloid leukemia patients with long‐term follow‐upSemantic proximity Read ↗

Genetic alterations and measurable residual disease in core binding factor acute myeloid leukemia.Semantic proximity Read ↗

Clinical characteristics and therapeutic determinants of RUNX1::RUNX1T1 differ from those of CBFB::MYH11 acute myeloid leukemiaSemantic proximity Read ↗

Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia.Semantic proximity Read ↗

[Prognostic value of KIT and other clonal genetic mutations in core-binding factor acute myeloid leukemia].Semantic proximity Read ↗

KIT and FLT3-ITD Mutations Do Not Predict Outcomes in Pediatric Core-Binding Factor Acute Myeloid Leukemia: Findings from the C-HUANAN-AML-15 Multicenter Cohort StudySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.